Cystoscopy and cytology remain the standard for diagnosis, but a plethora of urinary biomarkers could someday be a useful adjunct to NMIBC surveillance. Urine cytology, however, also has several known ...

Bladder biopsy of normal-looking mucosa, as determined by cystoscopy, might not add clinical value in patients with positive voided-urine cytology after treatment of non-muscle-invasive bladder cancer ...

Take the urology clinical quiz. How would you diagnose and treat a former smoker with a filling defect in the left kidney?

Lumea and AIxMed team up to bring AI driven urine cytology to Lumea's platform, targeting improved bladder cancer diagnostics. SANTA CLARA, Calif., May 30, 2025 /PRNewswire/ -- AIxMed, an innovator in ...

Biomarkers have value in the diagnosis and monitoring of bladder cancer, but their use is still being perfected. The value of using biomarkers in bladder cancer is compelling, though experts in the ...

AIxMed, an innovator in AI diagnostics for urine cytology and Lumea, a leading provider of primary clinical digital pathology solutions, announced a new partnership. This collaboration will integrate ...

Lumea will integrate AIxURO into its established digital pathology ecosystem, which is utilized by a significant portion of the U.S. urology market. The addition of this urine cytology AI further ...